Pipeline
Pliant Therapeutics is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-β1 signaling inhibition.
PLN-74809
Dual selective inhibitor of aVβ6/aVβ1
Idiopathic Pulmonary Fibrosis
Stage of Development
Primary Sclerosing Cholangitis
Stage of Development
PLN-1474
Selective inhibitor of aVβ1
F3/F4 NASH – Associated Liver Fibrosis
Stage of Development
Program 3
Inhibitor of aVβ8
Oncology
Stage of Development
Program 4
Anti-integrin mAb
Muscular Dystrophies
Stage of Development
Early Stage
Undisclosed targets
Various
Stage of Development
Pliant’s lead program, PLN-74809, is a small-molecule, dual selective inhibitor of αVβ1 / αVβ6 for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). These integrins cause upstream activation of TGF-β1 in actively fibrotic tissue. Inhibition of these integrins will block TGF-β1 activation, thereby preventing the growth of fibrotic tissue within the lung and bile ducts. PLN-74809 is being evaluated in Phase 2a trials in patients with IPF.
Pliant’s second program, PLN-1474, is an oral, small-molecule, selective inhibitor of TGF-ß activation by the integrin αVβ1 for the treatment of end-stage liver fibrosis in NASH. Clinical testing is anticipated to start in 2020.
Pliant has additional programs in IPF leveraging a tissue-specific approach to modulating TGF-β1 activation. Epithelial cells and fibroblasts have emerged as principal players in fibrosis pathophysiology. Our animal models confirm that selectively targeting TGF-β1 activation in these cells holds great therapeutic promise.
Pliant is also focused on developing small molecules to selectively target transcriptional regulation of epithelial-to-mesenchymal-transition (EMT), a process that is induced by TGF-β1. By selectively targeting EMT, Pliant aims to target many fibrotic diseases through novel mechanisms.
Pliant Therapeutics, Inc.
260 Littlefield Avenue,
South San Francisco, CA 94080
info@pliantrx.com
650.481.6770